Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.48 |
| ▸ | CA2 | P00918 | 8/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1022230 | 0.86 | CA1 (0.38) | CA1CA2CA12CA7CA13 | |
| SCHEMBL4502132 | 0.84 | CA1 (0.58) | CA1CA2CA12CA7CA13 | |
| SCHEMBL29668992 | 0.83 | CA12 (0.39) | CA1CA2CA12CA7CA13 | |
| SCHEMBL19613260 | 0.83 | CA12 (0.39) | CA1CA2CA12CA7CA13 | |
| SCHEMBL25357619 | 0.79 | CA1 (0.48) | CA1CA2CA12CA7CA13 | |
| SCHEMBL20237716 | 0.76 | CA1 (0.48) | CA1CA2CA12CA7CA13 | |
| SCHEMBL29505942 | 0.76 | CA1 (0.48) | CA1CA2CA12CA7CA13 | |
| SCHEMBL25357808 | 0.75 | CA1 (0.43) | CA1CA2CA12CA7CA13 | |
| SCHEMBL6676829 | 0.73 | CA1 (0.40) | CA1CA2CA12CA7CA13 | |
| SCHEMBL29505948 | 0.73 | CA1 (0.40) | CA1CA2CA12CA7CA13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265055-A1 | STAT INIHIBITORY COMPOUNDS AND COMPOSITIONS | OXFORD FINANCE LLC | 2023-08-24 | — | — | US | disclosed |
| WO-2022051639-A1 | STAT INHIBITORY COMPOUNDS AND COMPOSITIONS | JANPIX LIMITED (US) | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265055-A1 | STAT INIHIBITORY COMPOUNDS AND COMPOSITIONS | STAT5B, STAT5A, STAT3 | CA1 4704/4885CA2 4486/4885CA12 4701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.